IASLC Schl f Thracic Onclgy Prgram Chicag--Octber 14, 2016 Philadelphia--Octber 21, 2016 San Francisc-- Nvember 4, 2016 Financial/Cmmercial Relatinships DISCLOSURES All individuals able t influence r cntrl cntent f any CME certified activity that will be presented were required t cmplete a Financial Relatinships/Cnflicts f Interest Disclsure Frm prir t the live activity. A Cnflict f Interest (COI) is created and exists when individuals in a psitin t cntrl the cntent f CME, r their spuses/partners, that have a relevant persnal financial relatinship within the past 12 mnths with a cmmercial interest that prduces, markets, re-sells, r distributes health care gds r services cnsumed by, r used, n patients that benefits the individual in any financial amunt and therefre, may bias their pinins and teachings. This may include receiving a salary, ryalty, intellectual prperty rights, cnsulting fee, hnraria, wnership interest (e.g., stcks, stck ptins r ther wnership interest, excluding diversified mutual funds), r any ther financial benefit. Financial benefits are usually assciated with rles such as emplyment, management psitin, independent cntractr (including cntracted research and clinical trials), cnsulting, speaking and teaching, membership n advisry cmmittees r review panels, bard membership, and ther activities fr which remuneratin is received r expected. This IASLC CME educatinal activity was planned and develped t: uphld academic standards t ensure balance, independence, bjectivity, and scientific rigr; adhere t requirements t prtect health infrmatin under the Health Insurance Prtability and Accuntability Act f 1996 (HIPAA); and, include a mechanism t infrm learners when unapprved r unlabeled uses f therapeutic prducts r agents are discussed r referenced. IASLC CME assures that the planners/reviewers/authrs/faculty/peer reviewers et. al. cnflicts f interest were identified, reviewed and reslved frm all individuals invlved in the develpment r able t influence and cntrl the cntent f this CME activity; IASLC CME assures that disclsure is given prir t an educatinal activity being delivered t learners. Any individual wh failed r refused t disclse relevant financial relatinships was disqualified frm this CME activity and remved frm any f IASLC CME activity presentatin.
All cmmercial relatinships and cnflicts f interest that are identified are thrughly vetted by IASLC Ethics Cmmittee, CME Subcmmittee, and Independent reviewer. COI will be evaluated by the Bard f Directrs f the IASLC fr fair balance, scientific bjectivity f studies utilized in this activity, and patient care recmmendatins. IASLC CME is cmmitted t prviding its learners with high-quality CME activities and related materials that prmte imprvements r quality in health care and nt a specific prprietary business interest f a cmmercial entity. The fllwing Financial Disclsures are frm the, reviewers, speakers, planning cmmittee members (et.al.) their spuse/life partner have disclsed regarding financial interest/arrangement r affiliatin with any cmmercial interests that prduce, market, re-sell, r distribute healthcare gds r services fr patients that are relevant t this presentatin(s) r that have prvided cmmercial supprt fr this cntinuing medical educatin activity. CREDIT STATEMENT IASLC is accredited by the Accreditatin Cuncil fr Cntinuing Medical Educatin (ACCME) t prvide cntinuing medical educatin fr physicians. IASLC CME designates this Internet Live Curse activity fr a maximum f 8.0 AMA PRA Categry 1 Credits. Physicians shuld claim nly the credit cmmensurate with the extent f their participatin in the activity. FINANCIAL SUPPORT This educatinal activity was cmmercially supprted by: Merck. GOAL & PURPOSE Participants will learn abut tbacc cntrl and smking cessatin prgrams and hw t implement them in their daily practice. Participants will update their knwledge n early detectin and screening. Participants will be infrmed abut the pssibilities fr cntinuus medical educatin. They will learn abut clinical trial designs and hw t becme successful investigatrs f c-perative research grups. TARGET AUDIENCE This CME activity is designed t meet the educatinal needs f healthcare prfessinals wh diagnse and treat patients with lung cancer, including medical nclgists, thracic surgens, pulmnlgists, radiatin nclgists, radilgists, pathlgists and advanced practice nurses and physicians' assistants.
LEARNING OBJECTIVES Recall significance f histlgical subtyping f lung carcinmas. Discuss labratry practices and requirements fr bimarker testing. Outline current therapeutic appraches fr limited and extensive small cell lung cancer (SCLC). Describe current therapeutic appraches fr patients with mesthelima and thymma. DISCLAMER Participants have an implied respnsibility t use the newly acquired infrmatin t enhance patient utcmes and their wn prfessinal develpment. The infrmatin presented in this activity is nt meant t serve as a guideline fr patient management. Any prcedures, medicatins, r ther curses f diagnsis r treatment discussed r suggested in this activity shuld nt be used by clinicians withut evaluatin f their patient s cnditins and pssible cntraindicatins n dangers in use, review f any applicable manufacturer s prduct infrmatin, and cmparisn with recmmendatins f ther authrities. Thank yu fr yur participatin.
Reviewer: Laurie Gaspar, MD Planners: Pia Hirsch Carls Ferreira Octber 14, 2016-Chicag Faculty/Speakers: Sanja Dacic, MD Jyti Patel, MD Kristin Higgins, MD David Berkvitz, MD Harvey Pass, MD Research Supprt frm: NCI/NIH, NHLBI, CDC, DOD, Belluck and Fx, NYU Cancer Center, Patient Philanthrpy, Genentech. Hnraria: Astra Zeneca, IASLC, AATS Octber 21, 2016-Philadelphia Faculty/Speakers: Anthny Gal, MD Crey Langer, MD Kristin Higgins, MD Chris Manley, MD Matthew Steliga, MD Research Supprt frm: Celgene; BI; AZ; Clvis; Merck; GSK, EMD/Sern, Advantage, Invi. Cnsultant: Celgene, BI, AZ, Clvis, Lilly, BMS, Merck, Vertex; Genentech/Rche; Astra Zeneca, IASLC, AATS; Abbvie; synta; Lilly and Amgen. Nvember 4, 2016-San Francisc Faculty/Speakers: Fred Hirsch, MD, PhD Speaker/Advisry Bard: Advisry bards: Genentech/Rche, Lilly, AstraZeneca, BMS, Merck, Ventana, Nvartis, HTG. Jnathan Reiss, MD Research Supprt frm: Astra Zeneca, Nvartis, Merck, Millenium.
Megan Daly, MD James Jett, MD Cnsultant: Medtrnic, Clvis, Celgene, Ariad. Hnraria: Celgene, Genentech. Travel: Genentech, Astra Zeneca.. Speaker/Advisry Bard: Lilly, Ariad, Chiasma. Emplyee: Oncimmune (bimarkers) emplyee. Stck Optins: fr Oncimmu. Leah Bachus, MD Mary Redman, MD..
TO RECEIVE CME CREDIT: Upn cmpletin f the electrnic evaluatin link the CME Certificate will be ready fr yu t print r save fr yur recrds. This infrmatin is used nt nly t evaluate the present activity, but als t plan fr future prgrams. Participants wh cmplete a pst-test alng with an evaluatin will receive 10.5 AMA PRA Categry 1 Credit(s) fr each cmpleted webinar